Related Experiment Video
Updated: Jan 23, 2026

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
Published on: August 1, 2013
Correlates of time to approval and other clinical development periods
Christopher D Breder1, Margaret VanHeusen2, Lin-Chau Chang3
1Advanced Academic Programs, Krieger School of Arts and Sciences, Johns Hopkins University, Washington, DC; Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract:
The drug development cycle is classically divided into a clinical phase and review phase, with the clinical phase typically being further partitioned based on the planning and conduct of adequate and well controlled trials. Factors affecting the duration of the development intervals have not previously been systematically investigated. Here, we analyze a large population (N=825) of New Drug Applications (NDAs) approved between 2008 and 2017 to characterize the typical duration of these intervals and the development factors associated with their duration. These data and analyses will help those involved in pharmaceutical development by enabling data-driven planning and by providing insight into the effect of certain factors on the duration of drug development programs.
Insights
This study analyzed 825 New Drug Applications (NDAs) to understand drug development timelines. Key factors influencing the duration of clinical and review phases were identified to aid pharmaceutical planning.
Area of Science:
- Pharmaceutical Science
- Drug Development
- Regulatory Science
Background:
- The drug development cycle traditionally includes clinical and review phases, with clinical trials being a key component.
- Systematic investigation into factors influencing the duration of these development intervals is lacking.
- Understanding these timelines is crucial for efficient pharmaceutical development.
Purpose of the Study:
- To systematically investigate factors affecting the duration of drug development intervals.
- To characterize the typical duration of clinical and review phases for New Drug Applications (NDAs).
- To provide data-driven insights for pharmaceutical development planning.
Main Methods:
- Analysis of a large population (N=825) of New Drug Applications (NDAs).
- Data collected from NDAs approved between 2008 and 2017.
- Statistical analysis to identify factors associated with development interval durations.
Main Results:
- Characterization of typical durations for drug development intervals.
- Identification of specific factors that influence the length of these intervals.
- Quantitative insights into the drug development process.
Conclusions:
- The study provides a systematic analysis of drug development timelines.
- Identified factors can inform data-driven planning in pharmaceutical development.
- Insights gained can help optimize the efficiency of bringing new drugs to market.
More Related Videos
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
11:29Real-time Video Projection in an MRI for Characterization of Neural Correlates Associated with Mirror Therapy for Phantom Limb Pain
Published on: April 20, 2019
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Periodic Classification of the Elements
Correlations
The Periodic Table
Correlation and Causation
Correlation versus Causation
If the dependent variable increases or decreases when the independent variable increases, there is a positive or negative...